Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma
Oncology/Hematology > Skin Cancer — Two-year survival in second line for patients with BRAF/NRAS wild-type tumors by Charles Bankhead, Senior...
Arden Culton
Oncology/Hematology > Skin Cancer — Two-year survival in second line for patients with BRAF/NRAS wild-type tumors by Charles Bankhead, Senior...
